Skip to main content

Table 1 Plating efficiency (PE) and surviving fraction (SF) values in AsPC-1, Capan-2 and BxPC-3

From: Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

 

AsPC-1

Capan-2

BxPC-3

PE %

SF %

PE %

SF %

PE %

SF %

Control

42.88

100.00

50.07

100.00

30.63

100.00

24 μM Erlo

34.28

79.94

43.50

86.88

19.37

63.22

Low concentrations of Nelfinavir and Nitroxoline

 12 μM Nelfi

14.00

32.65

20.97

41.88

11.43

37.32

 10 μM Nitro

0.00

0.00

0.73

1.46

2.70

8.81

 12 μM Nelfi + 10 μM Nitro

0.00

0.00

0.83

1.66

4.50

14.69

 24 μM Erlo + 12 μM Nelfi + 10 μM Nitro

0.00

0.00

0.80

1.60

2.00

6.53

High concentrations of Nelfinavir and Nitroxoline

 25 μM Nelfi

0.00

0.00

1.20

2.40

0.23

0.76

 40 μM Nitro

0.00

0.00

0.57

1.13

0.20

0.65

 25 μM Nelfi + 40 μM Nitro

0.00

0.00

0.47

0.93

0.20

0.65

 24 μM Erlo + 25 μM Nelfi + 40 μM Nitro

0.00

0.00

0.23

0.47

0.17

0.54